pharmaphorum4m
Lilly's Alzheimer's drug gets UK nod but won't be NHS-funded
The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to ...
UK regulator approves second Alzheimer’s drug in months but government won’t pay for it
Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after an independent watchdog agency said the treatment isn’t worth the cost to ...
Eli Lilly’s Alzheimer’s drug donanemab rejected for NHS use
The U.K. watchdog declines to endorse Eli Lilly's Alzheimer's drug donanemab, citing lack of value for the NHS and ...
Drug which slows Alzheimer's rejected for NHS use because of 'value'
A new Alzheimer’s drug has been rejected for widespread use in the health service in England after the health spending ...
i29m
Second Alzheimer’s ‘wonder drug’ blocked for use on NHS due to high costs
NHS spending watchdog said donanemab, which would have been available to around 70,000 people in England and Wales, "does not ...
New Alzheimer’s drug rejected for NHS use – because it’s not worth the money
New Alzheimer’s drug rejected for NHS use – because it’s not worth the money - Alzheimer’ patients in UK left behind over ...
London Evening Standard37m
Alzheimer’s drug rejected for widespread use by NHS spending watchdog
A new Alzheimer’s drug has been rejected for widespread use in the health service in England after the health spending ...
Donanemab – what we know about the latest Alzheimer’s drug
Donanemab is a targeted antibody drug which slows down the early stages of Alzheimer’s. The drug, and another new drug for ...
Hereford Times57m
Donanemab trial patient: ‘I feel as normal as a 78-year-old can be’
A retired journalist who took part in the clinical trial for the new Alzheimer’s drug has described how he feels “as normal as a 78-year-old can be”. Peter Almond finished a trial for donanemab in ...
Historic house with six acres of land on sale in UK city for £200k less than London flat
A historic coach house with six acres of land, stables and a host of outbuildings close to one of Britain's most popular ...
National Institute for Health and Care Excellence59m
New Alzheimer’s treatment donanemab does not currently demonstrate value for the NHS says NICE
Donanemab (also called Kisunla and made by Eli Lilly) has been licensed today by the MHRA for treatment of mild cognitive impairment or mild dementia due to Alzheimer’s disease in some adults. It is a ...